The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Savannah Resources Jumps On Deal With Rio Tinto

Mon, 22nd Jun 2015 10:20

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Carnival, up 4.1% at 3,308 pence. Deutsche Bank upgrades Carnival to Buy from Hold, lifting its price target to 3,525p from 3,400p, with the bank saying it expects the second-quarter results from the cruiser operator to be above the upper end of the company's guidance. Analyst Richard Carter says he expects Carnival to demonstrate further booking and pricing recovery coupled with more operational momentum in its Carnival brand.

Sky, up 3.2%. Shares in the broadcaster are higher after the Murdoch family is reported to have rejected bids for its stake in Sky, stoking speculation that they intend to make a new attempt to take full control of the company, the Daily Telegraph reported on Saturday. The most recent bid is understood to have come from Vivendi, the French media conglomerate, while Vodafone Group also made an informal approach for the Murdoch's stake in Sky last year, the newspaper said.

Severn Trent, up 2.9% Canadian investment giant Borealis Infrastructure is considering a GBP5 billion approach for Severn Trent, two years after the FTSE 100 water company rejected an earlier takeover attempt, The Sunday Times reported. The newspaper, citing "sources close to the situation", said it is understood that the two sides opened talks last month, and discussions are at an early stage with no certainty a deal.

Capita, up 2.2%. The outsourcing company said that NHS England has named it as the preferred bidder to establish a single provider framework for administrative support functions for primary care across the UK. Capita said its selection includes an initial contract to manage and deliver services in England. The four-year sole provider framework has a maximum total value of GBP1 billion. Under the framework, the initial contract, which runs for seven to 10 years, for Capita to provide administrative support services for primary care in England is expected to be valued at up to about GBP400 million.
-------
FTSE 100 LOSERS
-------
Randgold Resources, down 1.8%, Fresnillo, down 0.7%. Precious metals miners are amongst the handful of FTSE 100 stocks which are trading lower Monday after the price of gold sunk below USD1,200 an ounce. Gold currently trades at USD1,195.35.
-------
FTSE 250 WINNERS
-------
Spire Healthcare Group, up 9.3%. The private healthcare provider said the major shareholder in South Africa-based private hospital group Mediclinic has acquired a 29.9% stake in the company for GBP432 million. The shareholder, Remgro, has acquired the stake in Spire at 360 pence per share. Spire shares closed at 320 pence on Friday. Spire said the intention is for Mediclinic to acquire the stake in Spire from Remgro in the "near future". Mediclinic and Remgro have confirmed they have no intention to acquiring the rest of Spire.

Bwin.Party Digital Entertainment, up 2.1%. The online gaming operator shares are higher after it said it has agreed to sell its entire interest in World Poker Tour to Ourgame International Holdings for USD35 million in cash. Bwin.party Digital Entertainment said it will continue to sponsor a number of World Poker Tour events and television shows in the US and Europe until the end of December 2016, and will have first refusal on any sponsorship opportunities that could become available until the end of December 2016.
-------
FTSE 250 LOSERS
-------
WS Atkins, down 1.4%. Panmure Gordon downgraded the project designer, engineer and management consultancy to Hold from Buy, saying the current share price does not reflect the near-term risks in its rail business.
-------
AIM ALL-SHARE WINNERS
-------
Savannah Resources, up 85%. The company said it has established a joint venture with mining giant Rio Tinto, which will result in both companies combining their heavy mineral sands projects in Mozambique. Under the deal, Savannah's Mutamba, Dongane and Jangamo prospects, together called the Jangamo project, will be combined with Rio Tinto's Chilubane project. Those prospects border one another and Savannah will operate the joint venture and have the ability to earn up to a 51% stake in the newly combined project by conducting the scoping, pre-feasibility and feasibility studies. Rio Tinto shares are up 0.3%.

Imaginatik, up 38%. The Consultancy and technology products company on Friday said it knows of no reason for the rise in its share price last week. However, it said it is aware that Quob Park Estates has been acquiring shares in the company. It added it has not received a notification of Quob's interest in its shares and has had no contact with the investment vehicle.

Lansdowne Oil & Gas, up 18%. The company said PSE Seven Heads and a subsidiary of PSE Kindsale Energy has entered into a contract with Diamond Offshore Drilling UK for the Ocean Guardian drilling rig to be used to drill a well at the Midleton Prospect in the North Celtic Sea. Kinsale Energy holds an 80% interest in the SEL 4/07 licence, with Lansdowne owning the remaining 20%. PSE Seven Heads is the operator of the licence.

ReNeuron Group, up 12%. The stem cell therapy company said it has extended its existing research collaboration with Australia-based Benitec Biopharma following positive results from early studies conducted by the pair.
-------
AIM ALL-SHARE LOSERS
-------
Armstrong Ventures, off 20%. The investment company said it is "hopeful" about the future, as it said it is operating against tough conditions, which it doesn't see improving in the near term. Chariman Haresh Kanabar said the general market conditions have been difficult for small AIM-listed companies focused on the resources and energy sectors.

Richland Resources, down 13%. The company said it will delay its first sapphire sale to the third quarter of 2015, news which follows a consultation with sightholders. Richland Resources, which is developing the Capricorn Sapphire project, said it will hold a product display and education session on its first recovered sapphires at the time of the Hong Kong Jewellery show from this coming Thursday to Sunday.

By Daniel Ruiz; danielruiz@alliancenews.com; and Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.